IN2014DN07913A - - Google Patents

Info

Publication number
IN2014DN07913A
IN2014DN07913A IN7913DEN2014A IN2014DN07913A IN 2014DN07913 A IN2014DN07913 A IN 2014DN07913A IN 7913DEN2014 A IN7913DEN2014 A IN 7913DEN2014A IN 2014DN07913 A IN2014DN07913 A IN 2014DN07913A
Authority
IN
India
Prior art keywords
relates
rosacea
vesicular
administering
treatment
Prior art date
Application number
Inventor
John Mayo
William Henry
Original Assignee
Sequessome Technology Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequessome Technology Holdings Ltd filed Critical Sequessome Technology Holdings Ltd
Publication of IN2014DN07913A publication Critical patent/IN2014DN07913A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Fodder In General (AREA)

Abstract

The present invention relates to vesicular formulations for the treatment of rosacea. It also relates to a method of treating rosacea comprising administering a vesicular formulation according to the invention.
IN7913DEN2014 2012-03-29 2013-03-28 IN2014DN07913A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1205642.0A GB201205642D0 (en) 2012-03-29 2012-03-29 Vesicular formulations
PCT/EP2013/056694 WO2013144289A1 (en) 2012-03-29 2013-03-28 Vesicular formulations

Publications (1)

Publication Number Publication Date
IN2014DN07913A true IN2014DN07913A (en) 2015-04-24

Family

ID=46159988

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7913DEN2014 IN2014DN07913A (en) 2012-03-29 2013-03-28

Country Status (19)

Country Link
US (1) US9555051B2 (en)
EP (1) EP2830630A1 (en)
JP (1) JP2015511618A (en)
KR (1) KR20150004798A (en)
CN (1) CN104349782A (en)
AU (1) AU2013241701A1 (en)
BR (1) BR112014024033A8 (en)
CA (1) CA2867749A1 (en)
CL (1) CL2014002547A1 (en)
CO (1) CO7121334A2 (en)
EA (1) EA038899B1 (en)
GB (2) GB201205642D0 (en)
IL (1) IL234747A0 (en)
IN (1) IN2014DN07913A (en)
MX (1) MX2014011516A (en)
NZ (1) NZ700472A (en)
PH (1) PH12014502065A1 (en)
SG (1) SG11201406144TA (en)
WO (1) WO2013144289A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178502A1 (en) 2009-08-21 2012-03-29 Targeted Delivery Technologies Ltd Vesicular formulations
CA2971642A1 (en) * 2014-12-23 2016-06-30 Camurus Ab Controlled-release formulations
HRP20210903T1 (en) 2015-06-30 2021-09-17 Sequessome Technology Holdings Limited Blended formulations
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Method of administration and treatment
WO2022180199A1 (en) * 2021-02-25 2022-09-01 Exinov Emulsion for use in the treatment of rosacea

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60136511A (en) 1983-12-26 1985-07-20 Eisai Co Ltd Remedy and preventive for hyperuricemia
JPS63501289A (en) 1985-09-27 1988-05-19 ザ　リ−ジエンツ　オブ　ザ　ユニバ−シテイ　オブ　カリフオルニア Liposome transdermal drug delivery system
JPS6295134A (en) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk Production of liposome
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
WO1994001089A1 (en) 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
FR2714382B1 (en) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipids vector of active molecule, their preparation and their use in cosmetic or dermatological compositions.
DE4447287C1 (en) 1994-12-30 1996-11-07 Cevc Gregor Droplet-in-fluid composition to transport agent e.g. through skin
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (en) 1997-08-27 2000-02-18 Oreal USE OF A LIPID VEHICLE-BASED DISPERSION AS AN ANTI-INFLAMMATORY COMPOSITION
ES2169566T3 (en) * 1997-11-19 2002-07-01 Schering Ag COMPOSITION WITH AZELAIC ACID.
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
CA2345355A1 (en) 1998-09-01 2000-03-09 Idea Ag Electrically controlled transport of charged penetrants across barriers
ATE272391T1 (en) 1998-12-23 2004-08-15 Idea Ag IMPROVED FORMULATION FOR TOPICAL, NON-INVASIVE USE IN VIVO
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
MXPA02000053A (en) 1999-07-05 2003-07-21 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers.
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
DK1272161T3 (en) 2000-04-12 2008-05-19 Liplasome Pharma As Lipid-based system for delivery of drugs against parasitic infections
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
CA2448627A1 (en) 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
WO2003000190A2 (en) 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
CA2476859C (en) 2002-03-13 2011-09-20 Collagenex Pharmaceuticals, Inc. Water-based delivery systems
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP2006505619A (en) 2002-10-11 2006-02-16 アイディーイーエー アーゲー With improved deformability, including at least three amphiphiles, for improved transport through a semipermeable barrier and for non-invasive drug utilization in vivo, especially through the skin Agglomerates
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
JP2004131432A (en) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation Malignant tumor suppressor
US20070160656A1 (en) 2003-05-02 2007-07-12 Dziewiszek Krzysztof J Lipid platinum complexes and methods of use thereof
EP1658086A2 (en) 2003-07-21 2006-05-24 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
JP2005179313A (en) * 2003-12-24 2005-07-07 Shu Uemura:Kk Method for producing base agent for skin cosmetic, and skin cosmetic
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
EP1933856A4 (en) 2005-08-29 2008-11-19 Sepsicure L L C Method for treatment or prevention of conditions caused by gram-positive bacteria
EP2364701A1 (en) 2005-12-20 2011-09-14 Cenestra, Llc Omega-3 fatty acid formulations
JP5009547B2 (en) 2006-03-31 2012-08-22 株式会社コーセー Cosmetics containing pigments and liposomes
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
JP5660561B2 (en) 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド Use of glycerophospholipids for joint lubrication
JP4732307B2 (en) 2006-11-20 2011-07-27 株式会社アンズコーポレーション Nanoemulsion and cosmetics containing the same
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (en) 2008-01-23 2009-07-24 David Ceretta APPARATUS FOR MAKING MIXTURE ELEMENTS
ES2335636B1 (en) 2008-02-29 2011-05-11 Lipotec, S.A. COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF MIXED MICELAS.
JP2009256331A (en) 2008-03-25 2009-11-05 Nagase Chemtex Corp Agent for preventing, alleviating or treating hyperuricemia or gout
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
BRPI0924302A2 (en) 2009-02-05 2019-09-24 Targeted Delivery Tech Limited methods of reducing proliferation and viability of microbial agents
SG176297A1 (en) 2009-06-03 2012-01-30 John Charles Mayo Formulations for the treatment of deep tissue pain
SG178502A1 (en) 2009-08-21 2012-03-29 Targeted Delivery Technologies Ltd Vesicular formulations
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
US20160193147A1 (en) 2013-07-31 2016-07-07 Sequessome Technology Holdings Limited Vesicles

Also Published As

Publication number Publication date
GB2515440B (en) 2017-02-08
CO7121334A2 (en) 2014-11-20
BR112014024033A8 (en) 2017-07-25
KR20150004798A (en) 2015-01-13
AU2013241701A1 (en) 2014-10-16
CN104349782A (en) 2015-02-11
US20150057249A1 (en) 2015-02-26
GB201419075D0 (en) 2014-12-10
EP2830630A1 (en) 2015-02-04
GB201205642D0 (en) 2012-05-16
CL2014002547A1 (en) 2015-03-27
GB2515440A (en) 2014-12-24
MX2014011516A (en) 2015-04-08
WO2013144289A1 (en) 2013-10-03
PH12014502065A1 (en) 2014-12-10
NZ700472A (en) 2016-02-26
IL234747A0 (en) 2014-11-30
US9555051B2 (en) 2017-01-31
EA038899B1 (en) 2021-11-03
CA2867749A1 (en) 2013-10-03
BR112014024033A2 (en) 2017-06-20
JP2015511618A (en) 2015-04-20
EA201491581A1 (en) 2015-02-27
SG11201406144TA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
GB201103062D0 (en) Method
GB201118656D0 (en) New compounds
EA033374B9 (en) Solid pharmaceutical compositions comprising enzalutamide and method of treatment
PH12015502075B1 (en) Treatment of cataplexy
TN2015000278A1 (en) Autotaxin inhibitors
MX349004B (en) New compounds.
MX366899B (en) New compounds.
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
UA118610C2 (en) Spirocyclic inhibitors of cathepsin c
PH12014502032A1 (en) Treatment of brain cancer
PH12014502558A1 (en) Drug for preventing and/or treating polycystic kidney disease
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
PH12014502065A1 (en) Vesicular formulations
MX2013010050A (en) Proteasome inhibitor delanzomib for use in the treatment of lupus.
MX356317B (en) Treatment of symptoms associated with female gastroparesis.
IN2014DN03010A (en)
IN2013MU03118A (en)
EA201590615A1 (en) STIMULATING LACTATION COMPOSITIONS BASED ON PHOSPHATIDIDILSERIN
NZ728612A (en) Treatment of androgen deprivation therapy associated symptoms
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
HK1202249A1 (en) Vesicular formulations
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy